Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date05 Jan 2016 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis
This study is intended to evaluate the safety of V404 PDS in patients with chronic non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide clinically measurable benefit over an extended period of time in patients with chronic non-infectious uveitis.
Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD.
Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)
This study will evaluate the preliminary safety and efficacy of PDS 1.0 in patients with neovascular AMD.
100 Clinical Results associated with ForSight VISION4, Inc.
0 Patents (Medical) associated with ForSight VISION4, Inc.
100 Deals associated with ForSight VISION4, Inc.
100 Translational Medicine associated with ForSight VISION4, Inc.